Azer-cel demonstrates two additional Complete Responses
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Two additional patients have achieved complete responses, bringing the total to four out of seven in the trial cohort. The trial targets patients with relapsed/refractory diffuse large B-cell lymphoma who have previously failed multiple therapies. The company plans to continue monitoring the durability of responses as the trial progresses.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Imugene
- Imugene Receives A$20 million for Convertible Notes Issuance
- Imugene Receives $11.7m R&D Tax Refund
- First Australian Patient Dosed in Phase 1b azer-cel Trial
- Issuance of Convertible Notes & Warrants for up to $46m
- Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund
Later from Imugene
- Imugene OnCARlytics Patent Allowance in China
- Imugene Granted India Patent for Oncolytic Virotherapy CF33
- S&P DJI Announces March 2025 Quarterly Rebalance
- Azer-cel Granted FDA Fast Track Designation in Blood Cancer
- Notice of Extraordinary General Meeting/Proxy Form
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene